Q-omics provides the consensus-scored TRDN profile across patient tissues and cancer cell-line models. TRDN expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRDN is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TRDN RNA expression shows 11,416 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, HNSC, and TGCT as cancer lineages where TRDN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRDN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRDN survival associations across molecular data types. TRDN RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRDN RNA expression–survival associations across cancer types. High TRDN expression shows unfavorable associations in SCLC, KIRP, UVM and READ, but favorable associations in ACC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify ACC as the clearest survival context for TRDN RNA expression.
This table summarizes TRDN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TRDN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRDN shows lower tumor expression in HNSC, KIRC, BRCA, UCEC and READ and higher tumor expression in LUSC. The HNSC box plot shows higher TRDN RNA expression in normal versus tumor tissue (log2 FC = −2.301, t-test p = .003).
This table shows molecular features associated with TRDN in patient tissues and cancer cell lines. In patient samples, TRDN shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TRDN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
